{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:36:17Z","timestamp":1788212177666,"version":"build-2803163510"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1645,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>\n                                 <jats:bold>Autoimmune hepatitis (AIH) typically responds to treatment in 90% of patients. Early prediction of treatment outcome would be advantageous in clinical practice. We evaluated whether parameters at initiation of therapy or changes in these parameters at day 3 and day 7 following corticosteroid initiation predicted treatment failure. Treatment-naive, jaundiced patients presenting to our tertiary unit between 1999-2009 were identified and mathematical models of prognosis in liver disease scores calculated at day 0, day 3, and day 7. Overall, 72 patients were identified (48 women, 24 men). Treatment failure occurred in 18% (13\/72) of patients. At diagnosis, higher median bilirubin (451 \u03bcmol\/L versus 262 \u03bcmol\/L,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.02), INR (1.62 versus 1.33,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.005), model for endstage liver (MELD) score (26 versus 20,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.02), MELD-sodium (Na) score (27 versus 22,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.03) and United Kingdom endstage liver disease score (UKELD) score (59 versus 57,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.01) significantly correlated with treatment failure. Analysis of area under the receiver operator characteristic curve (AUROC) values at day 7 identified change (\u0394) bilirubin (AUROC 0.68), \u0394 creatinine (0.69), \u0394 MELD (0.79), \u0394 MELD-Na (0.83) and \u0394 UKELD (0.83) best predicted treatment failure. Specifically, a fall in UKELD of less than 2 points predicted treatment failure with a sensitivity of 85% and specificity of 68%. Of 13 treatment failures, nine required second-line immunosuppression, three required emergency transplant, and one died of sepsis. In total, four patients died in the treatment failure group compared with one in the responder group (4\/13 = 31% versus 1\/59 = 1.7%,<\/jats:bold>\n                                 <jats:bold>\n                                    P\n                                 <\/jats:bold>\n                                 <jats:bold>= 0.003).<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>Approximately 20% of icteric AIH presentations fail corticosteroid therapy. This is associated with significant mortality and the need for emergency transplantation. Treatment failure is best predicted by change in MELD-Na and UKELD at day 7. Early identification of nonresponders may allow timely escalation of immunosuppression to prevent clinical deterioration. (Hepatology 2011;)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.24141","type":"journal-article","created":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T23:41:02Z","timestamp":1293061262000},"page":"926-934","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":109,"title":["Early Predictors of Corticosteroid Treatment Failure in Icteric Presentations of Autoimmune Hepatitis \u0394"],"prefix":"10.1097","volume":"53","author":[{"given":"Andrew D.","family":"Yeoman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Westbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Zen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Maninchedda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard C.","family":"Portmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"O'Grady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip M.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Heneghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-23-20250207","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/jhep.2002.30991","article-title":"Current and novel immunosuppressive therapy for autoimmune hepatitis.","volume":"35","author":"Heneghan","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R2-23-20250207","doi-asserted-by":"crossref","first-page":"448453","DOI":"10.1016\/0016-5085(88)90503-3","article-title":"Features reflective of early prognosis in corticosteroidtreated severe autoimmune chronic active hepatitis.","volume":"95","author":"Czaja","year":"1988","journal-title":"Gastroenterology"},{"key":"R3-23-20250207","doi-asserted-by":"crossref","first-page":"866871","DOI":"10.1016\/S0168-8278(94)80251-3","article-title":"The nature and prognostic implications of autoimmune hepatitis with an acute presentation.","volume":"21","author":"Nikias","year":"1994","journal-title":"J Hepatol"},{"key":"R4-23-20250207","doi-asserted-by":"crossref","first-page":"578582","DOI":"10.1016\/S0168-8278(97)80364-9","article-title":"Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation.","volume":"27","author":"Herzog","year":"1997","journal-title":"J Hepatol"},{"key":"R5-23-20250207","first-page":"297300","article-title":"Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis.","volume":"17","author":"Viruet","year":"1998","journal-title":"P R Health Sci J"},{"key":"R6-23-20250207","doi-asserted-by":"crossref","first-page":"625631","DOI":"10.1016\/S1542-3565(04)00246-0","article-title":"Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis.","volume":"2","author":"Kessler","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R7-23-20250207","doi-asserted-by":"crossref","first-page":"820833","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis.","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"key":"R8-23-20250207","first-page":"221227","article-title":"Failure of customary treatment in chronic active liver disease: causes and management.","volume":"8","author":"Schalm","year":"1976","journal-title":"Ann Clin Res"},{"key":"R9-23-20250207","doi-asserted-by":"crossref","first-page":"929938","DOI":"10.1016\/S0168-8278(99)80297-9","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.","volume":"31","author":"Alvarez","year":"1999","journal-title":"J Hepatol"},{"key":"R10-23-20250207","doi-asserted-by":"crossref","first-page":"864871","DOI":"10.1053\/he.2000.5852","article-title":"A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.","volume":"31","author":"Malinchoc","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R11-23-20250207","first-page":"15161523","article-title":"Evaluation of model for endstage liver disease for prediction of mortality in decompensated chronic hepatitis B.","volume":"101","author":"Chan HLY CA, Lau","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R12-23-20250207","doi-asserted-by":"crossref","first-page":"700706","DOI":"10.1016\/j.jhep.2004.12.022","article-title":"MELD score is a better prognostic model than ChildTurcottePugh score or Discriminant Function score in patients with alcoholic hepatitis.","volume":"42","author":"Srikureja","year":"2005","journal-title":"J Hepatol"},{"key":"R13-23-20250207","doi-asserted-by":"crossref","first-page":"353358","DOI":"10.1002\/hep.20503","article-title":"MELD accurately predicts mortality in patients with alcoholic hepatitis.","volume":"41","author":"Dunn","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R14-23-20250207","doi-asserted-by":"crossref","first-page":"12821284","DOI":"10.1053\/jhep.2002.32532","article-title":"Model for endstage liver disease (MELD for predicting mortality in patients with acute variceal bleeding.","volume":"35","author":"Chalasani","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R15-23-20250207","doi-asserted-by":"crossref","first-page":"255261","DOI":"10.1053\/jhep.2001.26522","article-title":"Shortterm prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems.","volume":"34","author":"Wehler","year":"2001","journal-title":"HEPATOLOGY"},{"key":"R16-23-20250207","first-page":"11381145","article-title":"Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of endstage liver disease.","volume":"46","author":"MontanoLoza","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R17-23-20250207","doi-asserted-by":"crossref","first-page":"252257","DOI":"10.1136\/gut.2007.131730","article-title":"Selection of patients for liver transplantation andallocation of donated livers in the UK.","volume":"57","author":"Neuberger","year":"2008","journal-title":"GUT"},{"key":"R18-23-20250207","first-page":"575583","article-title":"Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre.","volume":"45","author":"AlChalabi","year":"2006","journal-title":"J Hepatol"},{"key":"R19-23-20250207","doi-asserted-by":"crossref","first-page":"159185","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis.","volume":"40","author":"Cook","year":"1971","journal-title":"Q J Med"},{"key":"R20-23-20250207","first-page":"735737","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis.","volume":"1","author":"MurrayLyon","year":"1973","journal-title":"Lancet"},{"key":"R21-23-20250207","doi-asserted-by":"crossref","first-page":"541547","DOI":"10.1002\/hep.510250308","article-title":"Autoimmune hepatitis in childhood: a 20year experience.","volume":"25","author":"Gregorio","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R22-23-20250207","doi-asserted-by":"crossref","first-page":"394401","DOI":"10.1016\/S0168-8278(99)80096-8","article-title":"Behavior and significance of autoantibodies in type 1 autoimmune hepatitis.","volume":"30","author":"Czaja","year":"1999","journal-title":"J Hepatol"},{"issue":"Suppl 11","key":"R23-23-20250207","first-page":"278","article-title":"Fulminant autoimmune hepatitis: clinical presentation, outcome and prognostic factors.","volume":"5","author":"Villamil","year":"2005","journal-title":"Am J Transpl"},{"key":"R24-23-20250207","first-page":"690713","article-title":"Chronic hepatitis: morphology and nomenclature.","volume":"7","author":"Ishak","year":"1994","journal-title":"Mod Pathol"},{"key":"R25-23-20250207","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1056\/NEJMra050408","article-title":"Autoimmune hepatitis.","volume":"354","author":"Krawitt","year":"2006","journal-title":"N Engl J Med"},{"key":"R26-23-20250207","first-page":"13891395","article-title":"Effects of serum aspartate transaminase levels in patients with autoimmune hepatitis influence disease course and outcome.","volume":"6","author":"AlChalabi","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R27-23-20250207","doi-asserted-by":"crossref","first-page":"13631369","DOI":"10.1016\/j.hep.2003.09.038","article-title":"Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone.","volume":"38","author":"Mathurin","year":"2003","journal-title":"HEPATOLOGY"},{"key":"R28-23-20250207","doi-asserted-by":"crossref","first-page":"15101516","DOI":"10.1111\/j.1572-0241.2004.30457.x","article-title":"Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy.","volume":"99","author":"Verma","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"R29-23-20250207","first-page":"215218","article-title":"Giant cell hepatitis in adults.","volume":"3","author":"Lotz","year":"1997","journal-title":"Pathol Oncol Res"},{"key":"R30-23-20250207","doi-asserted-by":"crossref","first-page":"572577","DOI":"10.1002\/hep.1840150403","article-title":"The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis.","volume":"15","author":"Bach","year":"1992","journal-title":"HEPATOLOGY"},{"key":"R31-23-20250207","doi-asserted-by":"crossref","first-page":"263270","DOI":"10.1016\/S1386-6346(02)00274-7","article-title":"Clinicopathological features of acuteonset autoimmune hepatitis.","volume":"25","author":"Okano","year":"2003","journal-title":"Hepatol Res"},{"key":"R32-23-20250207","doi-asserted-by":"crossref","first-page":"13471353","DOI":"10.1111\/j.1365-2036.2006.02894.x","article-title":"Clinical characteristics of fulminanttype autoimmune hepatitis: an analysis of eleven cases.","volume":"23","author":"Miyake","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"R33-23-20250207","doi-asserted-by":"crossref","first-page":"9961003","DOI":"10.1002\/lt.21036","article-title":"Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis.","volume":"13","author":"Ichai","year":"2007","journal-title":"Liver Transplant"},{"key":"R34-23-20250207","doi-asserted-by":"crossref","first-page":"947954","DOI":"10.7326\/0003-4819-137-12-200212170-00007","article-title":"Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.","volume":"137","author":"Ostapowicz","year":"2002","journal-title":"Ann Intern Med"},{"key":"R35-23-20250207","doi-asserted-by":"crossref","first-page":"17551761","DOI":"10.1016\/0016-5085(93)90656-W","article-title":"The nature and prognosis of severe cryptogenic chronic active hepatitis.","volume":"104","author":"Czaja","year":"1993","journal-title":"Gastroenterology"},{"key":"R36-23-20250207","doi-asserted-by":"crossref","first-page":"664670","DOI":"10.1016\/j.jhep.2007.05.011","article-title":"The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study.","volume":"47","author":"Bernal","year":"2007","journal-title":"J Hepatol"},{"key":"R37-23-20250207","doi-asserted-by":"crossref","first-page":"958963","DOI":"10.1056\/NEJM199510123331502","article-title":"Azathioprine for longterm maintenance of remission in autoimmune hepatitis.","volume":"333","author":"Johnson","year":"1995","journal-title":"N Engl J Med"},{"key":"R38-23-20250207","first-page":"668670","article-title":"Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis.","volume":"1","author":"Stellon","year":"1985","journal-title":"Lancet"},{"key":"R39-23-20250207","doi-asserted-by":"crossref","first-page":"781784","DOI":"10.1002\/hep.1840080414","article-title":"Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal.","volume":"8","author":"Stellon","year":"1988","journal-title":"HEPATOLOGY"},{"key":"R40-23-20250207","doi-asserted-by":"crossref","first-page":"10361040","DOI":"10.1016\/j.cgh.2008.04.006","article-title":"A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.","volume":"6","author":"Hlivko","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R41-23-20250207","doi-asserted-by":"crossref","first-page":"30633070","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R42-23-20250207","doi-asserted-by":"crossref","first-page":"32323236","DOI":"10.3748\/wjg.v13.i23.3232","article-title":"Lowdose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis.","volume":"13","author":"Larsen","year":"2007","journal-title":"World J Gastroenterol"},{"key":"R43-23-20250207","doi-asserted-by":"crossref","first-page":"805809","DOI":"10.1097\/01.mcg.0000139050.67178.be","article-title":"Efficacy of tacrolimus in the treatment of steroid refractory autoimmune hepatitis.","volume":"38","author":"Aqel","year":"2004","journal-title":"J Clin Gastroenterol"},{"key":"R44-23-20250207","first-page":"A61","article-title":"Low dose tacrolimus as treatment of severe autoimmune hepatitis: potential role in remission induction.","volume":"44","author":"Heneghan","year":"1999","journal-title":"Gut"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.24141","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201103000-00023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T16:58:15Z","timestamp":1738947495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201103000-00023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.24141","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}